

Results of the RESPOND-CRT

Subgroup analyses

MicroPort™ CRM

THE RESPOND CRT SYSTEM WITH SONR TECHNOLOGY IS NOT AVAILABLE FOR SALE OR DISTRIBUTION IN THE USA. LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE.

Turning the Tide for Poor Responders to CRT.

Poor Responders to CRT.

Patients with pre-existing conditions such as history of AF, renal dysfunction or LBBB with narrow QRS are less likely to respond to cardiac resynchronization therapy.[1,2]

What's more, these pre-existing conditions are prevalent in the CRT patient population.*

PREVALENCE OF PRE-EXISTING CONDITIONS

History of AF



Renal Dysfunction



Narrow QRS & LBBB



For these patients in particular, automatic sensor-based optimization can lead to even greater benefits because it allows for a personalized, continuous adjustment of the AV and VV settings to suit the patient's changing needs.[2]

* Figures based on patient population in the RESPOND-CRT study.

Higher Clinical Response

The RESPOND-CRT study showed that there was a significantly higher clinical response* with SonR™ in all subgroups at high risk of non-response.[2]



PATIENTS WITH AF HISTORY



PATIENTS WITH RENAL DYSFUNCTION



PATIENTS WITH LBBB & QRS<150MS

*Clinical response based on composite clinical critiera: Alive, Free from heart failure events, with an improved NYHA functional class or quality of life.

Higher LV Remodeling

Significantly higher LV remodeling response was observed with SonR vs. Echo in patients with LBBB and narrow QRS.[3]



PATIENTS WITH LBBB & QRS<150MS

48% of Super Responders with SonR™



PATIENTS WITH LBBB & QRS<150MS

Better Response

=

Better Outcome

38% less risk of All-cause deaths or HF hospitalization with SonR™ for patients with **LBBB and QRS <150ms**.[2]



PATIENTS WITH LBBB & QRS<150MS

52%

less risk of all-cause death or cardiovascular hospitalization with SonR™ for patients with **AF history**.[2]



PATIENTS WITH AF HISTORY

45%

less risk of all-cause death or cardiovascular hospitalization with SonR™ for patients with **renal dysfunction**.[2]



PATIENTS WITH RENAL DYSFUNCTION



The Respond CRT system™*

Turning the Tide for Poor Responders to CRT.

References

1. Brugada J. et al. Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. Eur Heart J. 2017 Mar 7; 38(10): 730–738.
2. Singh J., Aydin A., Murgatroyd F. et al. Automatic Contractility Sensor-Guided Optimization is Associated with Improved Outcomes in CRT Subgroups at High Risk of Non-response. Heart Rhythm 2017;14(Suppl.5):C-AB36-02.
3. Delnoy P.P., Singh J., Alzueta J. Repetitive CRT optimization is associated with significant echo-remodeling and improved clinical response in CRT-D patients with LBBB QRS<150ms. Heart Rhythm 2017;14 (Suppl.5):C-AB17-02.

*The Respond CRT System™ consists of a SonR CRT-D device with a SonRtip atrial lead. SonR CRT-D devices and SonRtip leads are manufactured in Italy by MICROPORT CRM S.r.l., Via Crescentino S.N., 13040 Saluggia (VC), Italy.

RE06300087 - B - EN

The Respond CRT system™ with SonR™ technology is not available for sale or distribution in the USA.